Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rituxan rituximab: Phase II; marketed to treat low-grade non-Hodgkin's lymphoma (NHL)

IDPH and partners DNA and ROCZ reported positive preliminary results in a

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE